| Autor: |
Sanches M; R&D, Zymeworks Inc , Vancouver, BC, Canada., D'Angelo I; One Amgen Center Dr, Amgen Inc ., Thousand Oaks, CA, USA., Jaramillo M; Human Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada., Baardsnes J; Human Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada., Zwaagstra J; Human Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada., Schrag J; Human Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada., Schoenhofen I; Human Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada., Acchione M; Human Health Therapeutics Portfolio, NRC-CNRC , Montreal, QC, Canada., Lawn S; R&D, Zymeworks Inc , Vancouver, BC, Canada., Wickman G; R&D, Zymeworks Inc , Vancouver, BC, Canada., Weisser N; R&D, Zymeworks Inc , Vancouver, BC, Canada., Poon DKY; R&D, Zymeworks Inc , Vancouver, BC, Canada., Ng G; Search and Evaluation, Abbvie Inc , North Chicago, Illinois, USA., Dixit S; R&D, Zymeworks Inc , Vancouver, BC, Canada. |
| Abstrakt: |
As biologics have become a mainstay in the development of novel therapies, protein engineering tools to expand on their structural advantages, namely specificity, affinity, and valency are of interest. Antibodies have dominated this field as the preferred scaffold for biologics development while there has been limited exploration into the use of albumin with its unique physiological characteristics as a platform for biologics design. There has been a great deal of interest to create bispecific and more complex multivalent molecules to build on the advantages offered by protein-based therapeutics relative to small molecules. Here, we explore the use of human serum albumin (HSA) as a scaffold for the design of multispecific biologics. In particular, we describe a structure-guided approach to the design of split HSA molecules we refer to as AlbuCORE, that effectively and spontaneously forms a native albumin-like molecule, but in a heterodimeric state upon co-expression. We show that the split AlbuCORE designs allow the creation of novel fusion entities with unique alternate geometries. We also show that, apart from these AlbuCORE fusion entities, there is an opportunity to explore their albumin-like small hydrophobic molecule carrying capacity as a drug conjugate in these designs. |
